Literature DB >> 811112

Estimation of hepatic bilirubin UDP-glucuronyl transferase in patients with noncirrhotic portal fibrosis and liver disease: Significance and limitations.

D V Datta, R Nair, C R Nair.   

Abstract

Using a micromethod, hepatic bilirubin UDP-glucuronyl transferase has been assayed in percutaneous needle biopsy samples obtained from patients with infectious hepatitis, postnecrotic cirrhosis, Gilbert's disease, noncirrhotic portal fibrosis (NCPF), granuloma of the liver, and extrahepatic portal vein obstruction. The results were compared with those obtained from 10 control subjects. Patients with cirrhosis and infectious hepatitis revealed normal bilirubin transferase levels, whereas those with Gilbert's disease showed significantly low enzyme levels. Many patients with NCPF, some with extrahepatic portal vein obstruction, and patients with granulomatous involvement of the liver demonstrated significantly low levels. This low hepatitic-enzyme activity was not associated with hyperbilirubinemia. The mechanism of such low values in NCPF and other disorders is not known. It is postulated that low heaptic-enzyme activity in noncirrhotic portal fibrosis is due to sparse smooth endoplasmic reticulum. This study also emphasizes that serum bilirubin may remain normal with very low hepatic-enzyme activity. Although induction of the microsomal enzyme bilirubin transferase was observed following phenobarbitone administration in noncirrhotic portal fibrosis, this was not apparent in patients with cirrhosis, possibly due to maximal enzyme induction having been achieved by endogenous substrate.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 811112     DOI: 10.1007/BF01070884

Source DB:  PubMed          Journal:  Am J Dig Dis        ISSN: 0002-9211


  9 in total

1.  Neonatal jaundice. A review.

Authors:  W W ZUELZER; A K BROWN
Journal:  Am J Dis Child       Date:  1961-01

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Treatment of Gilbert's syndrome with phenobarbitone.

Authors:  M Black; S Sherlock
Journal:  Lancet       Date:  1970-06-27       Impact factor: 79.321

4.  Hepatic bilirubin glucuronidation in Gilbert's syndrome.

Authors:  B F Felsher; J R Craig; N Carpio
Journal:  J Lab Clin Med       Date:  1973-06

5.  Determination of bromsulphthalein-glutathione conjugating enzyme activity in needle biopsy specimens of human liver.

Authors:  D V Datta; S Singh; A K Samanta; S Saha; M Mukherjee; O P Nirankari; P N Chhuttani; C R Nair
Journal:  Clin Chim Acta       Date:  1973-08-30       Impact factor: 3.786

6.  Ultrastructure of the liver in non-cirrhotic portal fibrosis with portal hypertension.

Authors:  B N Tandon; R Lakshminarayanan; S Bhargava; N C Nayak; S K Sama
Journal:  Gut       Date:  1970-11       Impact factor: 23.059

7.  Determination of bilirubin UDP-glucuronyl transferase activity in needle-biopsy specimens of human liver.

Authors:  M Black; B H Billing; K P Heirwegh
Journal:  Clin Chim Acta       Date:  1970-07       Impact factor: 3.786

8.  Hepatic bilirubin udp-glucuronyl transferase activity in liver disease and gilbert's syndrome.

Authors:  M Black; B H Billing
Journal:  N Engl J Med       Date:  1969-06-05       Impact factor: 91.245

9.  Determination of bilirubin glucuronide and assay of glucuronyltransferase with bilirubin as acceptor.

Authors:  F P Van Roy; K P Heirwegh
Journal:  Biochem J       Date:  1968-04       Impact factor: 3.857

  9 in total
  1 in total

1.  Pharmacokinetic study of chloramphenicol in patients with liver disease.

Authors:  A P Narang; D V Datta; N Nath; V S Mathur
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.